{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:06:31Z","timestamp":1759665991609},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In the largest clinical trial to date of immune checkpoint inhibitors for mesothelioma, patients treated with nivolumab\u2014either alone or in combination with ipilimumab\u2014posted impressive response rates and survival outcomes, according to data presented at the 2017 American Society of Clinical Oncology Annual Meeting. However, the combination, although more effective, was also more toxic.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nb2017-087","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T01:10:23Z","timestamp":1496884223000},"page":"OF7-OF7","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dual Checkpoint Blockade Takes Aim at Relapsed Mesothelioma"],"prefix":"10.1158","volume":"7","member":"1086","published-online":{"date-parts":[[2017,8,1]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/7\/8\/OF7\/6503\/Dual-Checkpoint-Blockade-Takes-Aim-at-Relapsed","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/7\/8\/OF7\/6503\/Dual-Checkpoint-Blockade-Takes-Aim-at-Relapsed","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T01:11:20Z","timestamp":1654564280000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/7\/8\/OF7\/6503\/Dual-Checkpoint-Blockade-Takes-Aim-at-Relapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":0,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,1]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2017-087","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,1]]}}}